Risk Prediction Model for Heart Failure and Cardiomyopathy After Adjuvant Trastuzumab Therapy for Breast Cancer

BACKGROUND: Adjuvant trastuzumab improves survival for women with human epidermal growth factor receptor 2‐positive breast cancer, but increases risk for heart failure (HF) and cardiomyopathy (CM). However, clinical trials may underestimate HF/CM risk because they enroll younger subjects with fewer...

Descripción completa

Detalles Bibliográficos
Autores principales: Ezaz, Ghideon, Long, Jessica B., Gross, Cary P., Chen, Jersey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://www.ncbi.nlm.nih.gov/pubmed/24584736
http://dx.doi.org/10.1161/JAHA.113.000472

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3959671/
https://www.ncbi.nlm.nih.gov/pubmed/24584736
http://dx.doi.org/10.1161/JAHA.113.000472

Ejemplares similares